Teclistamab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
DMC (Denmark), HAS (France) and HIRA (South Korea), among others, recommended or restricted teclistamab, while AOTMIT (Poland) did not recommend it.
The record spans 3.9 years, opening at AWMSG (Wales) on 4 Oct 2022 and running to 3 Sep 2026.
ZIN (Netherlands) changed its position: not recommended on 10 Jul 2024, recommended by 14 Apr 2025, after a resubmission.
No assessment is on file from PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
The file is active: 15 of 17 records date from 2023 or later.
4 distinct indication wordings are recorded for teclistamab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 17 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess teclistamab, on 4 Oct 2022; HIRA (South Korea) did not open a file until 3 Sep 2026 — a wide spread of 3.9 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 9 of 16 dated records fall in 2024 alone.
4 of the 12 agencies here assessed teclistamab more than once, CIPM (Spain) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
teclistamab has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for teclistamab reads 8 recommended, 4 not recommended, 1 pending and 1 restricted, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2026 | Relapsed or refractory multiple myeloma (RRMM) | Recommended | source |
| CHUIKYO (Japan) | 12 Mar 2025 | テクベイリ: cost-effectiveness evaluation (designated at listing) | designated, analysis not started | source |
| NICE (England) | 13 Nov 2024 | NICE TA1015 | recommended (optimised) | source |
| HAS (France) | 23 Oct 2024 | Re-assessment of SMR and ASMR | SMR substantial | source |
| ZIN (Netherlands) | 10 Jul 2024 | Advies - niet vergoeden teclistamab (Tecvayli®) voor de behandeling van multipel myeloom | not reimbursed (sluis) | source |
12 further decisions for teclistamab, across 9 agencies, are not shown here. They include the most recent record on file, 3 Sep 2026 from HIRA (South Korea); its outcome is in the subscriber dataset. They link to 11 further source documents.
Related molecules
- selinexor — divergent outcome (recommended vs not recommended) on a shared indication
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
- rituximab — same ATC class L01F — Antineoplastics
- bevacizumab — same ATC class L01F — Antineoplastics
Coverage: 17 decisions for teclistamab from 12 agencies, 2022 to 2026. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.